HilleVax, Inc.
NASDAQ: HLVX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert M. Hershberg
- Employees
- 14
- Headquarters
- Boston, United States
- IPO year
- 2022
- Market cap
- $104.8M
- Website
- https://www.hillevax.com
Loading HLVX…
Loading profile data…Frequently asked questions about HLVX
What does HilleVax, Inc. (HLVX) do?
HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections....
Where does HLVX trade?
HilleVax, Inc. (HLVX) trades on the NASDAQ Global Select.
What sector is HLVX in?
HilleVax, Inc. (HLVX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of HilleVax, Inc.?
Robert M. Hershberg is the chief executive officer of HilleVax, Inc. (HLVX).
Where is HilleVax, Inc. headquartered?
HilleVax, Inc. is headquartered in United States.
Does HLVX pay a dividend?
HilleVax, Inc. (HLVX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HLVX go public?
HilleVax, Inc. (HLVX) completed its initial public offering in 2022.